Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00455325
Status:
COMPLETED
Last Update Posted:
2022-05-10
First Post:
2007-03-30
Brief Title:
Chloroquine to Treat People With Metabolic Syndrome Aim2 ARCH-MS
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Study Overview
Official Title:
Genotoxic Stress Atherosclerosis and Metabolic Syndrome-AIM 2
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ARCH-MS
Brief Summary:
Metabolic syndrome consists of a group of co-occuring conditions that increase an individuals risk of developing heart disease stroke and diabetes The purpose of this study is to evaluate the short-term effectiveness of chloroquine a protein-activation medication at improving metabolic syndrome
Detailed Description:
Metabolic syndrome is one of the most common disorders in industrialized countries It consists of abnormal serum lipids glucose intolerance elevated blood pressure and central obesity in the setting of insulin resistance The syndrome substantially increases the risk of developing diabetes and vascular disease but there is no clear unifying approach to treat this disorder In animals activation of the protein ataxia telangiectasia mutated ATM using the antimalarial drug chloroquine improves features of metabolic syndrome and decreases atherosclerosis a build-up of fatty plaque within arteries The purpose of this study is to evaluate the effectiveness of short-term treatment with low doses of chloroquine as a way of managing metabolic syndrome
Participants in this study will initially receive placebo for 3 weeks followed by increasing doses of chloroquine in three 3-week intervals Following each 3-week treatment participants will be admitted to the research center for one day There will be a period of no active treatment for 5 to 7 weeks following each admission to the research center to allow recovery from the blood drawing of the clamp procedure before the start of the next treatment interval
Participants in this study will initially receive placebo for 3 weeks followed by increasing doses of chloroquine in three 3-week intervals Following each 3-week treatment participants will be admitted to the research center for one day There will be a period of no active treatment for 5 to 7 weeks following each admission to the research center to allow recovery from the blood drawing of the clamp procedure before the start of the next treatment interval
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P50HL083762 | NIH | None | httpsreporternihgovquickSearchP50HL083762 |